Two decades of pharmacovigilance and clinical experience with highly purified rabies immunoglobulin F(ab’)2 fragments

Expert Review of Vaccines

Volumn 16, Issue 3, 2017, Pages 273-287

  Reveneau, Elisa ^a   Cottin, Pascale ^a   Rasuli, Anvar ^a  

^a SANOFI PASTEUR   (France)

Author keywords

immunization; immunoglobulin; post exposure prophylaxis; Rabies; vaccine

Indexed keywords

IMMUNOGLOBULIN F(AB')2 FRAGMENT; RABIES IMMUNOGLOBULIN; RABIES VACCINE; IMMUNOGLOBULIN F(AB) FRAGMENT;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHMA; BRONCHOSPASM; CLINICAL OUTCOME; DRUG APPROVAL; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TREATMENT FAILURE; DYSPNEA; GASTROINTESTINAL DISEASE; HUMAN; HYPERHIDROSIS; HYPOTENSION; PHASE 4 CLINICAL TRIAL (TOPIC); POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RABIES; RASH; RETROSPECTIVE STUDY; REVIEW; SKIN ALLERGY; TACHYCARDIA; URTICARIA; ANIMAL; IMMUNOLOGY; POSTMARKETING SURVEILLANCE;

ANAPHYLAXIS; ANIMALS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PHARMACOVIGILANCE; POST-EXPOSURE PROPHYLAXIS; PRODUCT SURVEILLANCE, POSTMARKETING; RABIES; RABIES VACCINES; RETROSPECTIVE STUDIES;

EID: 85013254096     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1080/14760584.2017.1244009     Document Type: Review

References (41)

1. World Health Organization. Rabies - Bulletin - Europe. Rabies information system of the WHO collaboration centre for rabies surveillance and research. [cited 2016 Jan 14]. Available from: http://www.who-rabies-bulletin.org/about_rabies/classification.aspx
2. Rupprecht CE, Hanlon CA, Hemachudha T., Rabies re-examined. Lancet Infect Dis. 2002;2:327–343.
3. World Health Organization. WHO expert consultation on rabies. Second report. Geneva:WHO; 2013. (WHO Technical Report Series No. 982).
4. Warrell MJ, Warrell DA. Rabies:the clinical features, management and prevention of the classic zoonosis. Clin Med. 2015;15:78–81.
5. Hampson K, Coudeville L, Lembo T, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015;9:e0003709.
6. World Health Organization. Rabies. 2016 [cited 2016 Jan14]. Available from: http://www.who.int/rabies/en/
7. World Health Organization. Rabies (Fact Sheet N°99). 2014 [cited 2016 Jan14]. Available from: http://www.who.int/mediacentre/factsheets/fs099/en/
8. Asian Rabies Expert Bureau. Asian rabies experts meet in Manila. 2009 [cited 2016 Sep16]. Available from: http://www.areb.info/sites/default/files/files/Meetings/AREB_Press_Release_2009_for_website.pdf
9. Global Alliance for Rabies Control. Global vaccine and immunization research forum:pre-exposure rabies vaccination (PreP) in children of endemic countries. 2014 [cited 2016 Sep16]. Available from: http://www.who.int/immunization/research/forums_and_initiatives/02_Briggs_GVIRF14_Pre_exposure_Rabiesvacc.pdf
10. Baltazard M, Bahmanyar M. [Field trials with rabies vaccine on persons bitten by rabid wolves]. Bull World Health Organ. 1955;13:747–772. French.
11. World Health Organization. Human and dog rabies vaccines and immunoglobulins, Geneva. 2015 Oct 12−13 [cited 2016 Jan14]. Available from: http://apps.who.int/iris/bitstream/10665/199176/1/WHO_HTM_NTD_NZD_201511_eng.pdf
12. Jentes ES, Blanton JD, Johnson KJ, et al. The global availability of rabies immune globulin and rabies vaccine in clinics providing direct care to travelers. J Travel Med. 2013;20:148–158.
13. World Health Organization. Rabies vaccines:WHO position paper. Wkly Epidemiol Rec. 2010;32:309–320.
14. Lang J, Simanjuntak GH, Soerjosembodo S, et al. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen:a field trial in Indonesia. MAS054 Clinical Investigator Group. Bull World Health Organ. 1998;76:491–495.
15. 2 pERIG and providing evidence of adequate vaccine-induced antibody responses when coadministered with rabies vaccine.
16. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module VI–management and reporting of adverse reactions to medicinal products. EMA/873138/2011 Rev. London:EMA; 2011.
17. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module I–pharmacovigilance systems and their quality systems. EMA/541760/2011. London:EMA; 2011.
18. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use:ICH E2A:clinical safety data management:definitions and standards for expedited reporting. 1994.
19. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use:ICH E2D:post-approval safety data management:definitions and standards for expedited reporting. 2003 Nov 12.
20. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use:ICH E2C (R2):periodic benefit-risk evaluation report (PBRER). 2003 Nov 12.
21. 2 pERIG as part of the recommended postexposure prophylaxis and importance of adhering to current recommendations.
22. Quiambao BP, Dy-Tioco HZ, Dizon RM, et al. Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin:one-year follow-up of patients with laboratory-confirmed category III rabies exposure in the Philippines. Vaccine. 2009;27:7162–7166.
23. Quiambao B, Gepanayao C, Bermal N, et al. Immunogenicity and safety of three intradermal anti-rabies vaccination regimens using purified Vero cell rabies vaccine. APCRI J. 2008;X:15–19.
24. Rüggeberg JU, Gold MS, Bayas J-M, et al. Anaphylaxis:case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25:5675–5684.
25. Wilde H, Khawplod P, Khamoltham T, et al. Rabies control in South and Southeast Asia. Vaccine. 2005;23:2284–2289.
26. Wilde H, Choomkasien P, Hemachudha T, et al. Failure of rabies postexposure treatment in Thailand. Vaccine. 1989;7:49–52.
27. Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization:Vaccine Adverse Event Reporting System (VAERS)–United States, 1991-2001. MMWR Surveill Summ. 2003;52:1–24.
28. Hinrichsen VL, Kruskal B, O’Brien MA, et al. Using electronic medical records to enhance detection and reporting of vaccine adverse events. J Am Med Inform Assoc. 2007;14:731–735.
29. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20(Suppl C):C40–C44.
30. Sanofi Pasteur. Application for inclusion of Equine F(ab’)2 antivenoms in the WHO model list for essential medicines. [cited 2016 Jan 14]. Available from: http://archives.who.int/eml/expcom/expcom15/applications/newmed/equine/antivenoms.pdf
31. Baldé MC, Chippaux J-P, Boiro MY, et al. [Clinical study of tolerance and effectiveness of a F(ab’)(2) polyvalent antienom for African snake bites in Kindia, Guinea]. Bull Soc Pathol Exot. 2012;105:157–161. French.
32. De Haro L, Lang J, Bedry R, et al. [Snake bite by European vipers. A multicenter study of tolerance to Viperfav, a new intravenous antivenom]. Ann Fr Anesth Reanim. 1998;17:681–687. French.
33. Boels D, Hamel JF, Bretaudeau Deguigne M, et al. European viper envenomings:assessment of Viperfav™ and other symptomatic treatments. Clin Toxicol (Phila). 2012;50:189–196.
34. Jackson AC. Current and future approaches to the therapy of human rabies. Antiviral Res. 2013;99:61–67.
35. Gogtay N, Thatte U, Kshirsagar N, et al. Safety and pharmacokinetics of a human monoclonal antibody to rabies virus:a randomized, dose-escalation phase 1 study in adults. Vaccine. 2012;30:7315–7320.
36. Serum Institute of India Ltd Pune India. A phase II/III, randomized, multi-centric, comparator-controlled study of the safety and neutralizing activity of a human monoclonal antibody to rabies (SII RMAb) administered in conjunction with rabies vaccine for post-exposure prophylaxis in patients following potential rabies exposure (CTRI number:CTRI/2012/05/002709). 2012 [cited 2016 Jul16]. Available from: http://www.ctri.nic.in/Clinicaltrials/pmaindet2php?trialid=4191
37. Bakker AB, Python C, Kissling CJ, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus:safety, tolerability, and neutralizing activity. Vaccine. 2008;26:5922–5927.
38. Randomized phase II trial on safety and neutralizing activity of CL184 and rabies vaccine versus human rabies immune globulin (HRIG) and rabies vaccine in children and adolescents. [cited 2016 Jan 14]. Available from: http://clinicaltrials.gov/show/NCT00708084
39. Crucell Holland BV. A randomized phase II trial to compare the safety and neutralizing activity of CL184 in combination with rabies vaccine vs. HRIG or placebo in combination with rabies vaccine in healthy adult subjects. 2008 [cited 2016 Jan14]. Available from: https://clinicaltrialsgov/ct2/show/NCT00656097
40. Crucell Holland BV. Rabies virus neutralizing activity and safety of CL184, a monoclonal antibody cocktail, in simulated rabies post-exposure prophylaxis in healthy adults. 2010 [cited 2016 Jan14]. Available from: https://clinicaltrialsgov/ct2/show/NCT01228383
41. Bharti OK, Madhusudana SN, Gaunta PL, et al. Local infiltration of rabies immunoglobulins without systemic intramuscular administration:an alternative cost effective approach for passive immunization against rabies. Hum Vaccin Immunother. 2016;12:837–842.• Prelininary demonstrating that administering a quantity of rabies immunoglobulin was just sufficient to infiltrate wound(s) irrespective of body weight, and avoiding systemic intramuscular administration may be a feasible way of reducing the dose of rabies immunoglobulin and associated cost in category III exposures without compromising efficacy. These results need to be confirmed in larger studies.